FDA Rejects Review of Moderna’s Flu Vaccine Application, Shares Slide 
FDA Warns Novo Nordisk Over Misleading Ozempic Ad Claims 
AstraZeneca Q1 2026 Earnings Surge on Strong Oncology and Rare Disease Drug Sales 
Orsted Q1 EBITDA Beats Expectations Despite U.S. Impairments 
Intermittent fasting doesn’t have an edge for weight loss, but might still work for some 
Innovent Biologics Shares Rally on New Eli Lilly Oncology and Immunology Deal 
Medicare to Cover GLP-1 Weight-Loss and Diabetes Drugs Starting July 1 
Novo Nordisk Raises 2026 Outlook on Strong Wegovy Demand 
AcadeMedia Q3 Profit Climbs as International and Adult Education Segments Drive Growth 
AI-Driven Inflation Raises U.S. Consumer Prices, Goldman Sachs Says 
Hantavirus Cruise Ship Outbreak Triggers Global Health Alert 
Daiichi Sankyo Stock Drops After Earnings Delay and Oncology Review 
Trump Invites Top CEOs Including Nvidia, Apple, Boeing to China Summit With Xi Jinping 
Coinbase Q1 2026 Earnings Miss Sends COIN Stock Lower Amid Crypto Market Slump 
Dell Stock Hits Record High After Trump Endorsement, AI Server Demand Fuels Rally 
Armani Group Eyes Strategic Stake Sale to Luxury Giants 
Novavax, Inc., a biotechnology company headquartered in Gaithersburg, Maryland, revealed on Friday, May 10, that it has signed a licensing deal with Sanofi, a global healthcare company. The deal is reportedly worth up to $1.2 billion.
In the announcement, Novavax said it would commercialize its brand of COVID-19 vaccine with Sanofi. Reuters reported that they also agreed to develop a new vaccine that will combine COVID-19 and influenza shots using the former's Matrix-M adjuvant.
Approved Financial Arrangement
For the financial part of the deal, Sanofi agreed to pay Novavax $500 million upfront and up to $700 million while their vaccine is in development. The companies will also launch sales milestone payments of up to $200 million.
In addition, Novavax will receive a double-digit percentage in royalty payments for the sales of each product that Sanofi develops with Matrix-M adjuvant or the COVID-19 and combination vaccines. On the other hand, Sanofi will take a 4.9% stake in Novavax worth $70 million.
Agreement on Commercialization of the Vaccines
As stated in the contract, Novavax will lead the commercialization of its COVID-19 vaccine for the rest of 2024. Next year, it will transfer most of this responsibility to Sanofi. The latter will not manage the commercialization in countries where Novavax has existing partnership deals, such as South Korea, Japan, and India.
Nations with purchase agreements with the company will also be off-limits for Sanofi. Sanofi will be the only one in charge of developing and commercializing the combined flu and COVID-19 vaccine for the rest of the world.
"This collaboration is important for Novavax and for global public health. Our new partnership combines Novavax's proprietary recombinant protein and nanoparticle technologies, Matrix adjuvant and R&D expertise with Sanofi's world-class leadership in launching and commercializing innovative vaccines," Novavax's president and chief executive officer, John C. Jacobs, said in a press release. "Together, we can broaden access to both our COVID-19 vaccine and our adjuvant to ensure more individuals can benefit from the protection vaccines can provide."
Sanofi's global head of vaccines R&D, Jean-Francois Toussaint, also commented, "We are excited by the prospect of combining Novavax's adjuvanted COVID-19 vaccine that has shown high efficacy and favorable tolerability, with our rich portfolio of differentiated flu vaccines that have demonstrated superior protection against flu and its serious complications."
Photo by: Novavax Press Assets
